Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 15/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 7/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | WNT1 | P04628 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | MST1R | Q04912 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933036 | 0.94 | MAPK1 (0.88) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL1933048 | 0.90 | MAPK1 (1.00) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL1932302 | 0.84 | AURKB (1.00) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL17240002 | 0.81 | MAPK1 (0.68) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL21708381 | 0.81 | MAPK1 (0.68) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL15726190 | 0.81 | MAPK1 (0.68) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL1932182 | 0.80 | AURKB (1.00) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL12553772 | 0.79 | MAPK1 (0.79) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL1932932 | 0.79 | MAPK1 (1.00) | MAPK1AURKBNTRK1YES1PIM1 | |
| SCHEMBL15884535 | 0.79 | MAPK1 (0.67) | MAPK1AURKBNTRK1YES1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | claimed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | claimed |
| EP-2504336-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | Æterna Zentaris GmbH (DE) | 2012-10-03 | — | — | EP | claimed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | claimed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | claimed |
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-8841456-B2 | 1,5-naphthyridine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841456-B2 | 1,5-naphthyridine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| EP-2504336-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | Æterna Zentaris GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K2 | MAPK1 26/4885AURKB 389/4885NTRK1 1078/4885 |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | NRAS, RAF1, KRAS | MAPK1 4/4885AURKB 3666/4885NTRK1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.